Why Did HEXO’s Stock Price Fall 26% on Wednesday?

There’s new hope in HEXO’s stock, even though the latest fix comes at the cost of a 26% fall in the share price.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canadian marijuana producer HEXO‘s (TSX:HEXO)(NYSE:HEXO) stock price fell more than 26% on Wednesday as investors reacted to a news release the company issued that morning.

What happened?

HEXO announced a $40 million underwritten public offering of its common stock early on Wednesday. The latest offering was priced at $0.77 per share. This is a 20% discount to the previous day’s closing price of $0.96 per share. Investors will also receive common share warrants that will allow them to buy shares at $0.96 each over the next five years.

The 52,000,000 shares offer will close by April 13. Even during an Easter Holiday, quick investment decisions have to be made.

The marijuana firm is desperate to recapitalize during this down market.

Why is HEXO desperate for new capital?

Management is battling to beat very tight deadlines imposed by the company’s bankers. A banking syndicate including the Canadian Imperial Bank of Commerce and the Bank of Montreal extended the company a $65 million credit facility. HEXO has drawn $35 million of that facility. The loan isn’t due yet, but the bankers have changed the term loan’s covenants twice this year.

The bankers have made new demands as the company’s liquidity position has deteriorated.

A March 27 update to the loan covenants brought tight conditions. It requires that management secures at least $15 million in firm equity financing agreements by April 10, and the company has to raise more than $40 million in net proceeds from an equity offering by April 30 this year.

Time is ticking, and I applaud management for showing serious efforts in complying with the banks’ new demands.

So what?

There’s a high likelihood that the latest offering will be successful. It is being underwritten by good investment bankers anyway. Underwriters usually commit to purchase any “left-over shares” if an offering gets under-subscribed.

The company could exceed its financing target if the underwriters take up the option to buy 7,800,000 shares.

A successful capital raise will be a good result. It will dampen bankruptcy alarms set-off by the Going Concern notice in the company’s latest financial statements. It’ll also prove that, for now, HEXO has the capacity to raise new financing and shore up its liquidity coffers even during a market crash.

Most noteworthy, HEXO stock public offering’s success today could show that investors still believe in the future prospects of the company, and management’s ability to deliver on its long-term goals.

That said, take note that investors are being offered free warrants and a significant equity discount. The warrants’ exercise price is set at the stock’s closing price on the previous day. Yet under normal circumstances, warrant exercise prices are set significantly above ruling market prices. And the shares are priced at a deep 20% discount to the previous day’s closing price. Such asset pricing speaks volumes about a distressed company’s desperation for new liquidity.

The deep discount and favourable pricing on warrants is a steep price for the company to pay to incentivize new investors to buy into the offering. It speaks to the desperation in management’s voice when asking for a bailout from shareholders.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »